Vertex Pharmaceuticals (VRTX) Cash & Equivalents (2009 - 2026)

Vertex Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $5.5 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 17.5% year-over-year to $5.5 billion in Q1 2026; TTM through Mar 2026 was $5.5 billion, a 17.5% increase from a year earlier, with the FY2025 full-year figure at $5.1 billion, up 11.27% from the prior year.
• Cash & Equivalents climbed to $5.5 billion in Q1 2026 per VRTX's latest filing, from $5.1 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.1 billion in Q3 2023 and bottomed at $4.6 billion in Q4 2024.
• The 5-year median for Cash & Equivalents is $7.6 billion (2022), against an average of $7.4 billion.
• Across the five-year window, Cash & Equivalents surged 54.58% in 2022 and slumped 55.93% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $10.5 billion in 2022, then decreased by 1.28% to $10.4 billion in 2023, then slumped by 55.93% to $4.6 billion in 2024, then climbed by 11.27% to $5.1 billion in 2025, then increased by 8.03% to $5.5 billion in 2026.
• Per Business Quant, the three latest VRTX Cash & Equivalents figures stand at $5.5 billion (Q1 2026), $5.1 billion (Q4 2025), and $4.9 billion (Q3 2025).